Cingulate (CING) Change in Accured Expenses (2021 - 2025)
Cingulate's (CING) quarterly Change in Accured Expenses came in at $1.3 million in Q4 2025, up 30.94% YoY from $1.0 million in Q4 2024, and up 253.76% on a QoQ basis from -$852914.0 in Q1 2025.
Cingulate (CING) Change in Accured Expenses (2021 - 2025) Analysis & Trends
Cingulate (CING) has 5 years of Change in Accured Expenses data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Change in Accured Expenses rose 30.94% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 million (up 123.25% YoY) and the FY2025 annual result came in at $1.5 million, up 132.33% from the prior year.
- Change in Accured Expenses climbed to $1.3 million in Q4 2025, from -$852914.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $3.7 million in Q4 2023 to a low of -$5.0 million in Q1 2024.
- A 5-year average of $32095.7 and a median of -$65122.0 in 2022 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 4205.72% — and 2024, when it sank 1292.24%.
- Tracing CING's Change in Accured Expenses over 5 years: stood at -$1.4 million in 2021, then soared by 153.79% to $759858.0 in 2022, then soared by 383.73% to $3.7 million in 2023, then plunged by 72.75% to $1.0 million in 2024, then surged by 30.94% to $1.3 million in 2025.
- The last three Change in Accured Expenses figures came in at $1.3 million (Q4 2025), -$852914.0 (Q1 2025), and $1.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.31 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Mar 31, 2025 | -852,914.00 |
| Mar 31, 2025 | -852,914.00 |
| Dec 31, 2024 | 1.00 Mn |
| Dec 31, 2024 | 1.00 Mn |
| Sep 30, 2024 | -404,330.00 |
| Sep 30, 2024 | -404,330.00 |
| Jun 30, 2024 | -142,889.00 |
| Jun 30, 2024 | -142,889.00 |
| Mar 31, 2024 | -5.00 Mn |
| Mar 31, 2024 | -5.00 Mn |
| Dec 31, 2023 | 3.68 Mn |
| Dec 31, 2023 | 3.68 Mn |
| Sep 30, 2023 | 544,458.00 |
| Sep 30, 2023 | 544,458.00 |
| Jun 30, 2023 | 1.33 Mn |
| Jun 30, 2023 | 1.33 Mn |
| Mar 31, 2023 | -358,777.00 |
| Mar 31, 2023 | -358,777.00 |